Summary
The claims largely do not align with the provided prescribing information. Only the indication claim is directly supported by the label; multiple claims about generics, brand naming, substitutions, and non-specified safety points are not supported by the label sections provided.
Category Scores
Accurate Statements
Alfuzosin is used to treat signs and symptoms of benign prostatic hyperplasia (BPH).
Indications and Usage
Unsupported Statements
Uroxatral is a brand-name form of the prescription drug alfuzosin.
Brand-name designation not explicitly stated in the provided label sections.
A generic Uroxatral would be a generic version of alfuzosin in a comparable dosage form and strength.
No label discussion of generics or equivalence to brand in dosage form/strength.
Alfuzosin is available as generic medication.
No explicit generic availability stated in the provided label sections.
The generic alfuzosin uses the same active ingredient as Uroxatral.
Label sections do not discuss generics or active ingredient compatibility.
The exact product name, strength, and tablet formulation can vary by country and manufacturer.
Not stated in the available label sections.
Listings for generic Uroxatral are usually labeled by the active ingredient: alfuzosin.
Not stated in the available label sections.
Pharmacy systems may show the drug as alfuzosin "extended-release" (or a similar formulation label), depending on the exact Uroxatral product being replaced.
Not stated in the available label sections.
Not all alfuzosin generics are the same as Uroxatral tablets.
Not stated in the available label sections.
Even with the same active ingredient, products can differ by release mechanism (for example, extended-release vs other formulations).
Not stated in the available label sections.
Even with the same active ingredient, products can differ by strength (mg).
Not stated in the available label sections.
Even with the same active ingredient, products can differ by how the tablet is designed to release the drug over time.
Not stated in the available label sections.
For BPH meds like alfuzosin, you generally want the same formulation type and dosing schedule as the Uroxatral product you were prescribed.
Not stated in the available label sections.
To switch safely, confirm with your pharmacist that the new product matches Alfuzosin formulation (extended-release vs the same type).
Not stated in the available label sections.
To switch safely, confirm with your pharmacist that the new product matches strength per tablet.
Not stated in the available label sections.
To switch safely, confirm with your pharmacist that the new product matches your prescribed dosing schedule.
Not stated in the available label sections.
If the replacement doesn’t match, the medication may not provide the same urinary symptom control or could change side effects.
Not stated in the available label sections.
If urinary symptoms don’t improve or worsen after switching, the most common fixes are: confirm the formulation and dose match the original.
Not stated in the available label sections.
If urinary symptoms don’t improve or worsen after switching, the most common fixes are: reassess dosing timing with your prescriber.
Not stated in the available label sections.
Some patients can also be sensitive to small differences in how a product releases medication.
Not stated in the available label sections.
Common side effects of alfuzosin products can include dizziness or lightheadedness (sometimes from blood pressure effects).
Label indicates dizziness in the context of postural hypotension; not phrased as a general 'common side effects' statement.
Common side effects of alfuzosin products can include fatigue.
Not stated in the available label sections.
Common side effects of alfuzosin products can include headache.
Not stated in the available label sections.
Common side effects of alfuzosin products can include sometimes gastrointestinal symptoms.
Not stated in the available label sections.
If dizziness is worse after switching, it’s worth reporting to your prescriber promptly.
Not stated in the available label sections.
In most places, alfuzosin is prescription-only.
Not stated in the available label sections.
If you’re seeing "no prescription" listings online, they may be unsafe or not regulated.
Not stated in the available label sections.
If urinary symptoms don’t improve or worsen after switching, the most common fixes are: confirm the formulation and dose match the original.
Not stated in the available label sections.
Contradictions
Important Omissions
Contraindications
Importance:
High
Boxed warnings
Importance:
High
Dosing safety (switching formulations; specific guidance on switching and tolerance)
Importance:
High
Pregnancy
Importance:
Moderate
Pediatric use
Importance:
Moderate
Generic Drug Substitution / Interchangeability
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label indicates potential for postural hypotension/dizziness; otherwise standard alpha-1 blocking agent safety profile.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Generics/substitution and brand naming claims are not supported by the label; address safety-critical label sections (contraindications, interactions, dosing, pregnancy/pediatric use)
Suggested Improvement
Limit statements about brand vs generic branding unless the label explicitly discusses brand naming. When discussing substitutions or generics, rely on labeling guidance or regulatory approvals. Include contraindications, boxed warnings, dosing specifics for switching formulations, and pregnancy/pediatric considerations.